How well are we doing in preventing HIV and how can we do better?

Slides:



Advertisements
Similar presentations
HIV/AIDS The Epidemic in ANE and E&E So what do we do now? Paul De Lay Senior Advisor on HIV/AIDS Office of HIV/AIDS.
Advertisements

Women and ARV-based Prevention: Challenges and Opportunities Tim Mastro, MD, DTM&H AIDS 2014 Melbourne, Australia 24 July 2014.
From “What If” to “What Now” Perspectives on ARVs and the Future of Treatment and Prevention Mitchell Warren Executive Director, AVAC IAS 2011, Rome.
Modelling HIV/AIDS in Southern Africa Centre for Actuarial Research (CARe) A Research Unit of the University of Cape Town.
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
The Global Response to AIDS: Achievements and Challenges for the Long Term Peter Piot Institute for Global Health Imperial College London.
Peter Piot Institute for Global Health 4 th December 2009 What I wish modelling could do for global health.
Doing the Right Thing Karen A. Stanecki XV International AIDS Conference.
The Global Response to AIDS: Does It Pass the Test for Women? Peter Piot Institute for Global Health Imperial College.
Epidemiology of HIV and Access to Prevention services, Tanzania Joint Biennial HIV National Response Review Stakeholders meeting. November, 2014 Blue Pearl.
AIDS 2014 – Ending the adolescent AIDS epidemic Ungdom og hiv Anne May Andersen, Norad.
The potential and challenges of ARV-based HIV prevention: An overview
Creating an AIDS-Free Generation The beginning of the end of AIDS Center for Strategic & International Studies Washington, DC March 22, 2012 Thomas R.
Biomedical Approaches to HIV Prevention HIV Research Catalyst Forum April 21, 2010, Baltimore, MD Monica S. Ruiz, PhD, MPH George Washington University.
HIV and AIDS Data Hub for Asia-Pacific Review in slides Key Affected Populations.
HIV and AIDS Data Hub for Asia-Pacific Review in slides Sri Lanka Last updated: December 2014.
HIV and AIDS Data Hub for Asia-Pacific HIV and AIDS Data Hub for Asia-Pacific Review in slides China 1.
HIV and AIDS Data Hub for Asia-Pacific 11 HIV and AIDS Data Hub for Asia-Pacific Review in slides Mongolia.
HIV and AIDS Data Hub for Asia-Pacific Review in slides Thailand.
HIV and AIDS Data Hub for Asia-Pacific HIV and AIDS Data Hub for Asia-Pacific Review in slides Vietnam.
Country gallery Malaysia. Basic socio-demographic indicators, Total population (thousands)26,572 Surface area329,847 sq. km Annual population.
HIV and AIDS Data Hub for Asia-Pacific Review in slides Papua New Guinea Last updated: July 2015.
HIV-infected subjects with CD4 350 to 550 cells/mm serodiscordant couples HPTN 052 Study Design Immediate ART CD Delayed ART CD4
Exploring the potential impact of ART in reducing HIV transmission. Geoff Garnett, Jeff Eaton, Tim Hallett & Ide Cremin Imperial College London.
INVESTING TO END THE AIDS EPIDEMIC: A NEW ERA FOR HIV RESEARCH & DEVELOPMENT HIV VACCINES WORKING GROUP & MICROBICIDES RESOURCE TRACKING E. Donaldson 1,
Assessing Costs and Impact on the Epidemic of Male Circumcision Catherine Hankins UNAIDS 5th IAS Conference on HIV Pathogenesis,
HIV and AIDS Data Hub for Asia-Pacific Review in slides Timor-Leste Last updated: December 2014.
Country gallery Maldives. Basic socio-demographic indicators, Total population (thousands)306 Annual population growth rate2.4 Population aged.
HIV and AIDS Data Hub for Asia-Pacific Review in slides Afghanistan Last updated: December 2014.
Key Affected Populations in Asia: Where are we and what is the way forward? Dr. Sai Subhasree Raghavan SAATHII, India Governing Council Member, IAS.
HIV and AIDS Data Hub for Asia-Pacific Review in slides Viet Nam Last updated: July 2015.
HIV and AIDS Data Hub for Asia-Pacific Review in slides India.
India Last updated: January 2016.
HIV and AIDS Data Hub for Asia-Pacific Review in slides Bhutan Last updated: January 2016.
HIV and AIDS Data Hub for Asia-Pacific Review in slides Lao PDR Last updated: July 2015.
HIV and AIDS Data Hub for Asia-Pacific Review in slides Afghanistan Last updated: January 2016.
HIV and AIDS Data Hub for Asia-Pacific Review in slides Timor-Leste Last updated: January 2016.
HIV and AIDS Data Hub for Asia-Pacific Review in slides Mongolia Last updated: December 2014.
HIV and AIDS Data Hub for Asia-Pacific Review in slides Pakistan Last updated: January 2016.
New Prevention Technologies Workshop Module 2: NPTs in context
HIV and AIDS Data Hub for Asia-Pacific Review in slides Myanmar Last Update: June 2015.
HIV and AIDS Data Hub for Asia-Pacific Review in slides China Last Updated: August 2015.
HIV and AIDS Data Hub for Asia-Pacific Review in slides India Last updated: March 2016.
HIV and AIDS Data Hub for Asia-Pacific Review in slides Timor-Leste.
HIV and AIDS Data Hub for Asia-Pacific Review in slides Sri Lanka.
HIV and AIDS Data Hub for Asia-Pacific Review in slides Pakistan.
HIV and AIDS Data Hub for Asia-Pacific Review in slides Pakistan Last updated: November 2014.
2008 International AIDS Conference UNGASS reporting Matthew Warner-Smith Monitoring and Evaluation Division UNAIDS 2008 International AIDS Conference Satellite.
HIV and AIDS Data Hub for Asia-Pacific Review in slides Sri Lanka Last updated: April 2016.
HIV and AIDS Data Hub for Asia-Pacific Review in slides Japan.
HIV and AIDS Data Hub for Asia-Pacific Review in slides Thailand Last updated: January 2016.
Prevention Science Gaps and the HIV/AIDS Pandemic Quarraisha Abdool Karim, PhD Head: CAPRISA Women and AIDS Pogramme Associate Professor in Epidemiology,
HIV/AIDS Epidemic in India Trends, Lessons, Challenges & Opportunities
IAS Satellite Session 25th July 2017 Daniel Were, PhD
Sri Lanka Last updated: September 2016.
Timor-Leste Last updated: January 2016.
Fiji Last updated: September 2016.
Data Hub for Asia-Pacific Review in slides Myanmar
Mongolia Last updated: April 2016.
India Last updated: September 2016.
Pakistan Last updated: July 2015.
Myanmar Last Update: September 2016.
Key Affected Populations
Antiretroviral therapy coverage in sub-Saharan Africa,
Global Optimization of the Response to HIV
Bhutan.
Fiji Last updated: July 2018.
Myanmar Last Update: November 2014.
Key Affected Populations
Progress on Voluntary Medical Male Circumcision for HIV prevention and How VMMC fits into UNAIDS ' ' target Julia Samuelson, Nurse epidemiologist.
Presentation transcript:

How well are we doing in preventing HIV and how can we do better? Peter Piot Institute for Global Health Global HIV/AIDS vaccine enterprise

PREVENTION WORKS BUT...

Community mobilisation, Thailand’s 100% Condom Program Pilot in Ratchaburi province Implementation on a national scale Structural approaches that have sought to reduce the HIV vulnerability of sex workers have ranged from policies to enforce condom use to programmes that sought to build solidarity among and empower sex workers. Assessment of the 100% condom use policy in Thailand revealed that condom use climbed to over 90% (figure 3).40 Similar outcomes were reported from a more recent study of the effect of a 100% condom use policy combined with efforts to build community solidarity among sex workers in Puerto Plata in the Dominican Republic (panel 4).41 Figure 3 Full-size image (42K) Increase in condom use reported by sex workers in sentinel serosurveillance Reproduced with permission form UNAIDS.40 Proportion of condom use with Reported STD nationally recent clients Source: UNAIDS Case Study: Evaluation of the 100% Condom Programme in Thailand, 2000. http://data.unaids.org/Publications/IRC-pub01/JC275-100pCondom_en.pdf

HIV Prevalence Declines in Pregnant Women As this slide shows, there have also been declines in HIV prevalence in pregnant women in recent years. There are a number of effective HIV prevention methods available today, including safer sex, safer injection practices, condom use, and male circumcision. There are, however, also social obstacles attached to each of these. And we have seen that, even when these interventions are fully funded and supported by states and social institutions, they have only been able to drive HIV infection rates down to a certain level. In order to further reduce HIV incidence we need new biomedical tools -- the most important of these will be an effective HIV vaccine. Source: National surveillance reports and UNAIDS/WHO/UNICEF, Epidemiological Fact Sheets on HIV and AIDS.  July 2008.

Behavioural change, impact in urban and semi-urban Zimbabwe M1: assuming behavioural change, better fit to surveillance data Natural decline in incidence ~1990 Accelerated decline in incidence, due to behaviour change ~2000 M0: without behavioural change Fitted models for Zimbabwe data in urban and semi-urban areas. The posterior modal simulation is plotted for model M0 (without behaviour change: dashed blue line); and for model M1 (with behaviour change: solid black line). The prevalence data are also shown as grey crosses and lines. HIV incidence (per 100 person years at risk) for the entire posterior sample of simulations is plotted. Each thin grey line is one simulation, the thick red line is the mode, and the dashed black lines show the 2.5th and 97.5th percentiles of the distribution of prevalence. Source: Hallett TB, et al. Epidemics 2009;1(2):108-117

R0 = β c D Basic reproductive rate Transmission probability Mean duration of infection Condom use ART Microbicides PrEP PMTCT Circumcision Clean needles VCT ART Mean number of contacts VCT Behavioural change Substitution therapy

Effectiveness of condoms in preventing STIs including HIV This review of prospective studies published 2000-2004 identified evidence that consistent condom use is associated with reduced transmission in HIV Source: Holmes KK, et al. Bull World Health Organ. 2004;82(6):454-61.

Source: UNAIDS, UNICEF & WHO, 2008; data provided by countries. Number and percentage of HIV-positive pregnant women receiving antiretroviral prophylaxis 2004 2006 2005 Number of HIV-positive pregnant women receiving anti-retrovirals Year 400 000 500 000 600 000 100 000 200 000 300 000 % of HIV-positive pregnant women receiving anti-retrovirals 5 30 35 15 20 25 40 10 2007 Only 35% of HIV positive pregnant women receiving ART Source: UNAIDS, UNICEF & WHO, 2008; data provided by countries.

Reduction of acquisition risk after male circumcision (A) South Africa (B) Kenya (C) Uganda >50% reduction in risk of acquisition for men Infection-Free Probability Cumulative sero-incidence Cumulative probabilities of HIV detection Source: (A) Auvert B, et al. PLoS Med 2005;2(11): e298, (B) Bailey RC, et al. Lancet 2007; 369:643–656 and (C)Gray RH, et al. Lancet 2007; 369:657–666.

RCT: Treatment of STIs Source: Ronald Gray, Plenary lecture - Biomedical HIV Prevention Trials (A Sisyphean Task). Cape Town, IAS conference. 19-22July 2009. http://www.ias2009.org/pag/

Decriminalisation

Concurrency Strong case in modelling for concurrency as a determinant of HIV in southern Africa BUT Empirical evidence is lacking Polygyny protective More research needed on sexual networks Standard definitions needed for concurrency What is the intervention?

Population impact of treatment as prevention Time trends resulting from application of universal voluntary HIV testing and immediate ART strategy for people who test HIV positive, in combination with other adult prevention interventions that reduce incidence by 40% Source: Granich RM, et al. Lancet 2009; 373: 48–57.

NO MAGIC BULLET

Combination prevention Source: Coates TJ, et al. Lancet 2008; 372:669–84.

Source: Hallett TB, et al. PLoS ONE 2008;3(5): e2212 Interaction of circumcision interventions with existing behaviour change programmes Four epidemic projections show: (i) no interventions, (ii) circumcision intervention with 90% coverage, (iii) a behaviour change intervention that leads to an average 30% reduction in partner change rate and 30% increase in condom use with casual partners, (iv) both the circumcision intervention and the behaviour change intervention. The output is HIV incidence per 100 person-years at risk (pyar). The time-scale relates to years since the circumcision intervention starts. (Note: Unlike in other simulations, here no compensation is made for the potential effects of AIDS mortality modifying the risk distribution in the population Projected effect of different prevention interventions on HIV incidence Source: Hallett TB, et al. PLoS ONE 2008;3(5): e2212

Effectiveness /efficacy and controversies Rates of HIV infection during typical and perfect use Source: Cates W. Technical advances in HIV prevention, in HIV/AIDS Annual Update 2006. In: Phair JP, ed. Clinical Care Options, 2006.

Know your epidemic Cambodia, 1988-2004 5000 10000 15000 20000 25000 30000 35000 40000 45000 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Male clients Sex workers Wife from husband Husband from wife Mother to child Number of new HIV infections by route of transmission Source: Peerapatanapokin and Brown, using Asia Epidemic Model

Know your epidemic Lithuania 2004 2008 Proportion of HIV diagnosed cases by transmission category Source: Strujeva O , et al. Poster CDC079 – HIV infection trends in Lithuania in 2004 – 2008. Cape Town, IAS conference. 19-22July 2009. http://www.ias2009.org/pag/

Source: www.avac.org/timeline-website/ HIV Prevention Research Time-line of Expected Efficacy Trial Results (AVAC) 2007 2008 2009 2010 2011 2012+ STEP (HVTN 502/ Merck 023) HSV-2 SUPPRESSION (HPTN 039) HPTN 035 CDC 4323 iPrEx CDC 4940 PHAMBILI Male Circumcision in HIV+ Men PARTNERS IN PREVENTION CDC 4370 PARTNERS PrEP MIRA CARRAGUARD ALVAC-AIDSVAX CAPRISA 004 FEM-PrEP MDP 301 HVTN 505 VOICE (MTN-003) HPTN 052 Source: www.avac.org/timeline-website/

AIDS IS NOT OVER

The prevention gap To have an impact with already efficient prevention methods, we need more coverage Percentage of population groups most at risk with access to prevention services, 2008 Source: WHO/UNICEF/UNAIDS. Towards Universal Access. Scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009.

Treatment Action Campaign (TAC), South Africa

Source: SIDALAC/UNAIDS. 2001 Preventive expenditure for men who have sex with men and % of AIDS cases among them Source: SIDALAC/UNAIDS. 2001

Cost Effectiveness

The long term view Stop generic response to heterogeneous problem Start structural interventions NOW Invest in professionals and institutions Donor indicators and incentives focus on long term impact Maximise programme efficiency R&D

Combination treatment + Combination prevention + Vaccine???